Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, Kreatech Ink Labeling Technology Licensing Agreement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Agilent Technologies and Kreatech Diagnostics today announced a licensing and supply agreement for the Dutch molecular diagnostic firm's ULS technology and products, broadening an existing collaboration between the two companies.

ULS is a direct chemical labeling technology that features a two-step labeling procedure "that allows the use of a broad range of fluorescent labels and haptens," the partners said in a statement. Nucleic acids can be labeled regardless of their length or composition, they added, making the technology "ideally suited" for reproducible and robust labeling of all species of DNA and RNA molecules, they added.

Financial and other terms of the deal were not disclosed.

In 2007, the two companies inked a licensing agreement for use of Kreatech's labeling technology with formalin-fixed, paraffin-embedded DNA tissue-extraction methods from Agilent.

"The new agreement fits very well into Kreatech's commercial strategy to become a significant supplier of products for the US market,” said Kees Moonen, CEO of Kreatech, in a statement.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.